Net income (loss) per share

6 Months Ended

12 Months Ended

Jun. 30, 2011

Dec. 31, 2010

Net income (loss) per share [Abstract]

Net income (loss) per share

12. Net income (loss) per share

The following table sets forth the information needed to compute basic earnings per share:

	Three Months Ended					Six Months Ended
	June 30,					June 30,
	2011		2010 Restated			2011		2010 Restated
	(in thousands except per share data)					(in thousands except per share data)
Basic net income (loss)	$	1,842	$	(31,573	)	$	12,841	$	(48,832	)
Effect of Dilutive Securities — MHR convertible note payable assumed conversion		-0-		-0-			923		-0-
Numerator for Diluted net income (loss) per share after assumed note conversion		1,842		(31,573	)		13,764		(48,832	)
Weighted average common shares outstanding:		52,076,602		43,338,432			52,064,171		42,711,367
Dilutive securities
Options		221,124		—			309,457		—
Warrants		2,626,629		—			3,476,116		—
Shares underlying MHR convertible note payable		—		—			7,051,183		—
Diluted weighted average common shares outstanding and assumed conversion		54,924,355		43,338,432			62,900,927		42,711,367
Basic net income (loss) per share	$	0.04	$	(0.73	)	$	0.25	$	(1.14	)
Diluted net income (loss) per share	$	0.03	$	(0.73	)	$	0.22	$	(1.14	)

For the three and six months periods ended June 30, 2011 and 2010, certain potential shares of common stock have been excluded from the calculation of diluted income (loss) per share because the exercise price was greater than the average market price of our common stock, and therefore, the effect on diluted loss per share would have been anti-dilutive. In addition incremental shares from the assumed conversion of the MRH note payable are excluded for the three month periods ended June 30, 2011 and 2010 and for the six month period ended June 30, 2010 as the effect of these shares is anti-dilutive in these periods. The following table sets forth the number of potential shares of common stock that have been excluded from diluted net income (loss) per share because their effect was anti-dilutive:

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2011		2010		2011		2010
Options to purchase common shares		2,759,476		3,187,116		2,671,143		3,187,116
Outstanding warrants		9,018,697		6,954,391		8,169,210		6,954,391
MHR convertible note payable		7,051,181		6.319.856		-0-		6,319,856
		18,829,354		16,461,363		10,840,353		16,461,363

15. Net Loss Per Share

     The following table sets forth the information needed to compute basic and diluted earnings per share for the years ended December 31, 2010, 2009 and 2008:

	Year Ended December 31,
	2010			2009 restated			2008
	(In thousands, except per share amounts)
Basic and diluted net loss	$	(56,909	)	$	(16,821	)	$	(24,388	)
Weighted average common shares outstanding, basic and diluted		46,206,803			34,679,321			30,337,442
Basic and diluted net loss per share	$	(1.23	)	$	(0.49	)	$	(0.80	)

     The following table sets forth the number of potential shares of common stock that have been excluded from diluted net loss per share because their effect was anti-dilutive:

	Year Ended December 31,
	2010		2009		2008
Options to purchase common shares		2,477,037		2,865,736		2,208,854
Outstanding warrants and options to purchase warrants		11,832,826		9,934,253		2,972,049
Novartis convertible note payable		—		14,944,980		7,537,921
MHR note payable		6,675,512		5,983,146		5,362,596
		20,985,375		33,728,115		18,081,420